A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccination in The Booster (3rd dose)
- Conditions
- healthy volunteerSafety and Immunological Response Intradermal COVID-19 vaccination
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 60
1.Males or females at least 18 years of age (inclusive), 2. Have completed primary series of COVID-19 vaccines (2 doses of Sinovac, AstraZeneca, or mRNA) between 6-10 weeks?, 3. Can understand Thai language through speaking, reading and writing?, 4. Able to communicate through electronic tools such as Google form or line., 5. Capable of attending all study visits according to the study schedule., 6. Capable of informed consent and provision of written informed consent before any study procedures
1. Have history of severe drug or vaccine allergy (anaphylaxis)?, 2. Have ever been detected COVID-19 infection?, 3.Have any history of contacting COVID-19 patient (high risk contact)?, 4. Positive result of antigen test kit?, 5. Have received blood transfusion, plasma, blood product, blood component, immunoglobulins, antiviral or antibodies within the last 90 days?, 6.Have history of cigarettes smoking, alcohol drinking and history of drug abuse? , 7. Being pregnant?, 8. Have unstable disease or could not control the symptom?, 9. Have history of immunodeficiency or been using immunosuppressant or steroid drugs?, 10. Have any unusual symptoms or medical history that considered unable to participate in the study?
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety at 7 days after vaccination adverse event
- Secondary Outcome Measures
Name Time Method Immune response at 2 and 12 weeks after 3rd dose IgG